Concepedia

Publication | Open Access

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

DOIFull Paper Access

1.6K

Citations

24

References

2014

Year

John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger,
New England Journal of Medicine

Abstract

Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).

References

YearCitations

Page 1